Cargando…
On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
Autor principal: | Boretti, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906570/ https://www.ncbi.nlm.nih.gov/pubmed/36752889 http://dx.doi.org/10.1007/s10238-023-01010-7 |
Ejemplares similares
-
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022) -
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022) -
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022) -
Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023) -
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)